Skip to main content

Table 1 Main characteristics of all studies included in the meta-analysis

From: Prognostic role of pre-treatment C-reactive protein/albumin ratio in esophageal cancer: a meta-analysis

Study

Country

Case number

High expression (%)

Pathological type

NAC (%)

Location

Tumor stage

Follow-up (months)

Cut-off value

Multivariate analysis

HRs provided from

Outcome

NOS score

Ishibashi 2018 [12]

Japan

143

75 (51.7)

Multiple

72 (50.3)

22/56/65

33/33/60/17

NR

0.085

Yes/No

Report/SC

OS/CSS

7

Kunizaki 2018 [13]

Japan

116

51 (44)

Squamous

NR

15/31/19

0-II36/III-IV29

Median 35.9

0.042

Yes/No

Report/SC

OS/CSS

7

Otowa 2017 [14]

Japan

149

114 (76.5)

Squamous

149 (100)

24/73/52

IIA24/IIB36/III89

NR

0.03

Yes

Report

OS

6

Shao 2015 [24]

China

633

140 (22.1)

Squamous

0 (0)

33/428/172

I106/IIa203/IIb92/III232

Median 39

0.012

Yes

Report

OS

7

Matsunaga 2019 [25]

Japan

163

69 (42.3)

Multiple

95 (58.3)

32/86/45

012/I48/II45/III54/IV4

NR

0.0375

No

SC

OS

7

Wei 2015 [22]

China

423

147 (34.8)

Squamous

NR

36/252/135

41/131/81/23

Median 35.7

0.055

Yes

Report

OS

8

Xu 2015 [23]

China

468

87 (18.6)

Squamous

0 (0)

155/64/249

I24/II181/IIIA121/IIIB+IIIC142

Median 49.9

0.5

Yes

Report

OS

9

Yu 2018 [26]

China

160

85 (53.1)

Squamous

0 (0)

26/104/30

I160

Median 71.8

0.023

Yes

Report

OS

5

  1. NAC neoadjuvant chemotherapy, NR not report, HR hazard ratio, SC survival curve, OS overall survival, CSS cancer-specific survival, NOS Newcastle-Ottawa Quality Assessment Scale